Vernal Biosciences, a Colchester, VT-based mRNA manufacturer and formulator of LNP-mRNA, closed a $21 million financing.
The round was led by Ampersand Capital Partners and Dynamk Capital, with existing investors Alloy Therapeutics and ATUM participating and new investor Charles River Laboratories, Inc.
The funds from this financing will support the company’s growth including the construction of full GMP capabilities scheduled to become operational in late 2023.
Led by Christian Cobaugh, CEO and Founder, Vernal offers a complete range of mRNA-related services and products ranging from sequence design and screening support, scaled-down and scaled-up manufacturing of high purity mRNA and LNP-mRNA, platform process development technologies, and ultimately GMP manufacturing, for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation.
Cobaugh will be joined on Vernal’s board by existing board member, Errik Anderson of Alloy Therapeutics, and new board members, David Anderson of Ampersand, and Gustavo Mahler of Dynamk.
FinSMEs
03/06/2022